Pms34 Taltz® (Ixekizumab) for Treatment of Psoriatic Arthritis in the United States: A Budget Impact Analysis

Abstract

UKA operations per year, r-UKA was more costly than t-UKA but offered better clinical outcomes, the estimated cost per QALY was £2,831. The results were more favourable to younger patients aged less than 55 and sensitive to case volumes and follow up period. Conclusions: r-UKA is cost-effective compared with t-UKA over a 5 year period. Results: are dependent on case volumes, follow up period and favours younger age groups.